CG Oncology Q1 net loss $34.5M; BLA submission on track for H2 2025

CG Oncology, Inc.

2025-Q1 EPS reported -$0.45 revenue$52,000

Net loss of $34.5M ($0.45/share) vs $16.9M ($0.36) a year ago; R&D spend rose to $27.5M.
Cash $688.4M as of March 31, 2025; expected to fund operations into first half of 2028.
BOND-003 Cohort C: 75.5% CR at any time; 24-month CR rate 42.3% by K-M; 97.3% progression-free at 24 months.
Cohort P: 90.5% high-grade recurrence-free survival at 3 and 9 months in BCG-unresponsive Ta/T1 disease.
Anticipates starting BLA submission for cretostimogene in HR BCG-unresponsive NMIBC in H2 2025.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0000950170-25-069825
form_type: 8-K
ticker: CGON
cik: 0001991792
company_name: CG Oncology, Inc.
filed_at: 2025-05-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:50.649848+00:00
generated_at: 2026-05-21T18:56:37.502054+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.7
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0000950170-25-069825
json_url: https://secwatch.observer/filing/0000950170-25-069825.json
markdown_url: https://secwatch.observer/filing/0000950170-25-069825.md
text_url: https://secwatch.observer/filing/0000950170-25-069825.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/0000950170-25-069825-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1991792/000095017025069825/ck0001991792-20250513.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0000950170-25-069825

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.